Literature DB >> 25365233

Recent advances in vascular disrupting agents in cancer therapy.

Elena Porcù1, Roberta Bortolozzi, Giuseppe Basso, Giampietro Viola.   

Abstract

Vascular disrupting agents (VDAs) are an important class of compounds that exhibit selective activity against pre-existing tumor vasculature, causing rapid shutdown of the tumor blood flow and consequent necrosis of the tumor mass. The VDAs can be divided into flavonoid compounds, which are related to flavone acetic acid, and tubulin-binding agents. Tubulin-binding agents represent the largest group of VDAs and are characterized by different chemical structures, although most of them are derivatives of the lead compound combretastatin (CA-4). They demonstrated clinical activity, although recent findings have established that they have insufficient activity as single agents. Several resistance mechanisms occur, such as the resistance of the tumor rim cells, while promising results have been described in combination with other chemotherapeutics.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25365233     DOI: 10.4155/fmc.14.104

Source DB:  PubMed          Journal:  Future Med Chem        ISSN: 1756-8919            Impact factor:   3.808


  15 in total

1.  Design, synthesis, in vitro, and in vivo anticancer and antiangiogenic activity of novel 3-arylaminobenzofuran derivatives targeting the colchicine site on tubulin.

Authors:  Romeo Romagnoli; Pier Giovanni Baraldi; Maria Kimatrai Salvador; Filippo Prencipe; Carlota Lopez-Cara; Santiago Schiaffino Ortega; Andrea Brancale; Ernest Hamel; Ignazio Castagliuolo; Stefania Mitola; Roberto Ronca; Roberta Bortolozzi; Elena Porcù; Giuseppe Basso; Giampietro Viola
Journal:  J Med Chem       Date:  2015-03-26       Impact factor: 7.446

2.  Rapid induction of apoptosis in chronic lymphocytic leukemia cells by the microtubule disrupting agent BNC105.

Authors:  Darcy Bates; Edmond J Feris; Alexey V Danilov; Alan Eastman
Journal:  Cancer Biol Ther       Date:  2016-01-30       Impact factor: 4.742

3.  Discovery of Novel 4-Arylisochromenes as Anticancer Agents Inhibiting Tubulin Polymerization.

Authors:  Wenlong Li; Wen Shuai; Feijie Xu; Honghao Sun; Shengtao Xu; Hong Yao; Jie Liu; Hequan Yao; Zheying Zhu; Jinyi Xu
Journal:  ACS Med Chem Lett       Date:  2018-09-25       Impact factor: 4.345

4.  GSK-3β controls autophagy by modulating LKB1-AMPK pathway in prostate cancer cells.

Authors:  Aijing Sun; Changlin Li; Ruibao Chen; Yiling Huang; Qi Chen; Xiangjun Cui; Huafeng Liu; J Brantley Thrasher; Benyi Li
Journal:  Prostate       Date:  2015-10-06       Impact factor: 4.104

5.  Selective and Marked Blockade of Endothelial Sprouting Behavior Using Paclitaxel and Related Pharmacologic Agents.

Authors:  Prisca K Lin; Jocelynda Salvador; Jun Xie; Kalia N Aguera; Gretchen M Koller; Scott S Kemp; Courtney T Griffin; George E Davis
Journal:  Am J Pathol       Date:  2021-09-24       Impact factor: 4.307

6.  CEST MRI monitoring of tumor response to vascular disrupting therapy using high molecular weight dextrans.

Authors:  Hanwei Chen; Dexiang Liu; Yuguo Li; Xiang Xu; Jiadi Xu; Nirbhay N Yadav; Shibin Zhou; Peter C M van Zijl; Guanshu Liu
Journal:  Magn Reson Med       Date:  2019-05-20       Impact factor: 3.737

7.  The vascular disrupting agent combretastatin A-4 phosphate causes prolonged elevation of proteins involved in heme flux and function in resistant tumor cells.

Authors:  Sanchareeka Dey; Sharda Kumari; Sarada Preeta Kalainayakan; James Campbell; Poorva Ghosh; Heling Zhou; Keely E FitzGerald; Maoping Li; Ralph P Mason; Li Zhang; Li Liu
Journal:  Oncotarget       Date:  2017-12-28

8.  High-affinity ligands of the colchicine domain in tubulin based on a structure-guided design.

Authors:  Oskía Bueno; Juan Estévez Gallego; Solange Martins; Andrea E Prota; Federico Gago; Asier Gómez-SanJuan; María-José Camarasa; Isabel Barasoain; Michel O Steinmetz; J Fernando Díaz; María-Jesús Pérez-Pérez; Sandra Liekens; Eva-María Priego
Journal:  Sci Rep       Date:  2018-03-09       Impact factor: 4.379

9.  Synthesis and Biological Evaluation of 2-Methyl-4,5-Disubstituted Oxazoles as a Novel Class of Highly Potent Antitubulin Agents.

Authors:  Romeo Romagnoli; Pier Giovanni Baraldi; Filippo Prencipe; Paola Oliva; Stefania Baraldi; Maria Kimatrai Salvador; Luisa Carlota Lopez-Cara; Andrea Brancale; Salvatore Ferla; Ernest Hamel; Roberto Ronca; Roberta Bortolozzi; Elena Mariotto; Elena Porcù; Giuseppe Basso; Giampietro Viola
Journal:  Sci Rep       Date:  2017-04-13       Impact factor: 4.379

10.  The Novel Antitubulin Agent TR-764 Strongly Reduces Tumor Vasculature and Inhibits HIF-1α Activation.

Authors:  Elena Porcù; Luca Persano; Roberto Ronca; Stefania Mitola; Roberta Bortolozzi; Romeo Romagnoli; Paola Oliva; Giuseppe Basso; Giampietro Viola
Journal:  Sci Rep       Date:  2016-06-13       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.